
Overview
Medical tech firm's preliminary Q4 2025 revenue grew 61% yr/yr to $15.2 mln
Preliminary full-year 2025 revenue rose 86% to $50.5 mln
Company added 101 new surgeon users in 2025, a 61% increase
Outlook
Carlsmed anticipates growing recognition and adoption of aprevo in 2026
Company focuses on operational excellence for next growth phase in 2026
Result Drivers
SURGEON USER BASE - Carlsmed added 101 new surgeon users in 2025, a 61% increase, driving revenue growth
APREVO PLATFORM - Increased adoption of aprevo platform technology contributed to Q4 revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue |
| $15.20 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Carlsmed Inc is $20.00, about 57.6% above its January 9 closing price of $12.69
Press Release: ID:nGNX9jtcKP
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.